We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

oncology innovation

Advertisement

cGxPJobs Banner

D3 Bio Wins FDA Breakthrough and Orphan Drug Designations for D3S-001 in KRAS G12C-Mutated Cancers

Shanghai – August 28, 2025 — D3 Bio, Inc., a clinical-stage precision oncology company, announced that the U.S. Food...

By cGxPwire Editor
August 28, 2025

Read More

Advertisement

cGxPJobs

Posts pagination

1 … 3 4

Recent Posts

01

.Tech

Persistent Launches AI Innovation Lab With IIT Kharagpur
May 9, 2026
02

Bio-Pharma

ALX Oncology Reports Durable HER2 Breast Cancer Data
May 9, 2026
03

.Tech

Mission Bio Unveils Single-Cell CRISPR T Cell Data
May 9, 2026
04

Pharma

Eisai and Biogen Receive FDA Extension for LEQEMBI
May 9, 2026
05

Bio-Pharma

TRexBio Reports New TRB-061 Data for Atopic Dermatitis
May 9, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website